menu 1
menu 2
menu 3
menu 4
menu 5
menu 6
menu 7

May 2008

AdnaGen® Announces the Submission of a Request for a Pre-IDE Determination Meeting with FDA for AdnaGen´s AdnaTest Breast Cancer for the Detection of Circulating Breast Tumor Cells
April 2008

AdnaGen® Announces Appointment of Chief Executive Officer
Welcome Dr. Wolfram Rodatz
October 2007 AdnaGen® signs exclusive agreement with Innogenetics® to develop and commercialize new multiplex oncology tests
AdnaGen® schließt mit Innogenetics® einen Lizenzertrag zur Entwicklung
und zur Vermarktung neuartiger Multiplex-Tumortests
September 2007 Second Annual AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development: Maximizing Opportunities for Personalized Treatment, September 17-20, 2007, Atlanta, Georgia
Titel: Predictive Value of Circulating Tumor Cells in Patients with Breast and Colon Cancer
January 2007 Innogenetics distribute AdnaGen's CE-marked kits for breast and colon cancer in Europe
September 2006 Innogenetics signs an exclusive option and evaluation agreement for a technology that may revolutionize prenatal testing
September 2006 DCU - 25th Anniversary "Detection and molecular profiling of circulating tumour cells"
September 2006 AACR - American Association for Cancer Research "New Technique Detects Early Metastasis of Breast Cancer"
September 2006 WebMed "Sensitive Test Detects Cancer Spread"
February 2006 OncoVista Inc. acquires controlling interest in AdnaGen
January 2005 Gen-Probe and AdnaGen sign License Agreement